| Drug Type Biological products | 
| Synonyms B7-H3 GADLEN directed (Shattuck Labs) | 
| Target | 
| Action modulators, inhibitors | 
| Mechanism CD276 modulators(CD276 antigen modulators), TCRDV2 inhibitors(T cell receptor delta variable 2 inhibitors), TCRGV9 modulators(T cell receptor gamma variable 9 modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | United States  | 07 Nov 2022 | 





